Over the past two decades clinicians and researchers have sought to bring mechanical circulatory support (MCS) to pediatric patients with heart failure. ECMO, IABPs, and VADs have all been used in infants and children as a bridge to myocardial recovery or as a bridge to transplant. However, until recently, a commitment by industry, government, and researchers towards the development of pediatric MCS has not been present, especially in the United States. Advancements in adult VAD design to smaller, quieter, and fully implantable pumps capable of complete outpatient support have sparked curiosity in the application of this technology to children. Also, the increasing success of palliating congenital heart disease is creating an ever-growing cohort of children and adolescents with heart failure. These changing demographics and technological advances have caused a refocus of attention. This is most clearly demonstrated by the international use of several established MCS pediatric and neonatal systems, by the FDA's increasing proclivity to allow the use of international pediatric VADs in the USA, and by the recent National Heart, Lung, and Blood Institute funding of several institutions to develop pediatric VADs. This review describes the different aspects of pediatric MCS including indications, the features of the various VADs, and their current application in children worldwide. (Int J Artif Organs 2006; 29: 920-37) 
INTRODUCTION
Support of the patient with a failing cardio-respiratory system resistant to medicinal therapy has been the driving force behind decades of research in mechanical circulatory support (MCS). MCS can now salvage many of these patients by establishing hemodynamic stability and adequate perfusion to vital organs. Historically, the population of pediatric patients with heart failure has been dwarfed by the corresponding adult population, currently approaching 4.7 million and increasing at a rate of 550,000 patients a year (1) . Accordingly, nearly all published data and previous technical development with mechanical assistance, especially long-term assistance for the failing heart, concern the adult patient.
Recently, changing demographics have required a refocus of attention. The improving results with single ventricle patients coupled with the successful palliations of the past (i.e. atrial switches and atrio-pulmonary Fontans) is creating an ever growing cohort of patients who are developing heart failure as children and adolescents. As is true with the corresponding adult population, heart transplantation alone will not adequately address the management needs of this group. Furthermore, in contrast to the adults on MCS destination therapy, children and adolescents in need of chronic MCS will need multiple devices throughout their lives. Thus, the overall need (number of devices and length of support) for MCS in children is growing rapidly. This need is being addressed in Europe, where two prominent companies have developed pediatric versions of their ventricular assist devices (VAD), namely, Medos Medizintechnik AG ® (the Medos HIA VAD ® ) and Berlin Heart ® (the EXCOR VAD ® ), which have collectively been used in almost 300 pediatric patients worldwide. This need has also been recognized in the US, as evidenced by the National Heart, Lung and Blood Institute's request in 2001 for the development of a pediatric VAD. In 2004, the institute awarded grants to five research facilities (Tab. I) including the Cleveland Clinic Lerner College of Medicine-CWRU, Ension Inc., Jarvik Heart Inc., the Milton S. Hershey Medical Center, and the University of Pittsburgh, totaling approximately 22.5 million dollars, for the development of pediatric MCS (2) . Such recognition by the international community along with the growing population at risk and the advancements in technology has incited a commitment to the development of pediatric devices by industry and researchers.
INDICATIONS
Appropriate application of MCS in children requires an understanding of the unique pathological features of pediatric heart failure as compared to adult heart failure. For example, right heart failure and pulmonary hypertension seen in the adult population are often secondary to left heart failure, whereas the corresponding pediatric pathology is often intrinsic or anatomic. Therefore, support of the systemic ventricle in pediatric patients may not consistently translate into improvement of the right heart function, as is seen in adults (3) . Another challenge in pediatric MCS of patients with congenital heart disease (CHD) can be cannulation. One must consider how the patient can be cannulated, not only in regards to what vessels or chambers to use, but to the internal and external cardiac anatomy with respect to septal defects, hypoplastic chambers, anomalous venous connections, and aortic interruption/coarctation. Defects including pulmonary atresia or a common atrium may not be amenable to VAD support. The identification and management of systemic to pulmonary shunts, both surgically created (i.e. Blalock-Taussig shunt) and pathological (i.e. aorto-pulmonary collateral arteries) is another necessary and often difficult step in the MCS of patients with CHD.
When a child presents with myocardial failure and is being considered for MCS, a thoughtful and stepwise approach must be taken so that the diagnosis of congenital heart or lung disease is not missed. Anomalous left coronary artery from the pulmonary artery (ALCAPA) can present much like a child with myocarditis or idiopathic cardiomyopathy. Unless this diagnosis is methodically ruled out oversights can be made, which is especially problematic since the myocardium of most of these patients will improve to a near-normal state with coronary transfer (4) . In addition, total anomalous pulmonary venous return has historically been an oftmissed diagnosis in the acidemic and profoundly hypoxic infant for which MCS is requested. Fortunately, improvements in echocardiography have made ruling out this diagnosis more straightforward.
The indications of MCS in children with CHD can be categorized in regards to the need for and timing of intervention. 1) Pre-operative Indications: Patients with a correctable cardiac lesion that have become unstable on maximal medical therapy. 2) Post-operative indications: Patients who cannot be weaned from bypass after corrective surgery or who have low cardiac output syndrome (LCOS) resistant to medical therapy in the ICU.
3) Non-operative: Patients who do not have a surgically correctable cardiac lesion but whose cardiac and respiratory dysfunction are thought to be reversible with MCS or require bridge to transplant with MCS; this category includes intrinsic causes of cardio-respiratory failure like myocarditis as well as extrinsic such as sepsis and acute respiratory distress syndrome. Application of MCS for any of these indications may be as a bridge to recovery, a bridge to transplant, or as destination therapy. For clarity, it should be noted that the term "successful explant" will refer to a patient surviving to myocardial recovery or heart transplantation, whereas the term "weaning" will refer specifically to bridging to myocardial recovery.
Pre-operative
Establishing adequate resuscitation prior to a surgical procedure is an essential aspect of surgical management that should not be overlooked. In some cases, medical stabilization does not suffice and MCS should be considered, as patients in extremis upon arrival to the operating room have poor surgical outcomes. Specific subpopulations to consider: arresting hypercyanotic patients with tetralogy of Fallot (5), patients with recalcitrant pulmonary hypertensive crises (i.e. late presenting Truncus Arteriosus) (6) or those with complications from catheter intervention(s) requiring surgical correction, such as coronary dissection or creation of severe aortic insufficiency and ventricular dilation after balloon valvuloplasty. Application of MCS is likely underutilized in the pre-operative cohort due to the fact that maximal medical therapy is often not abandoned until the situation becomes irreversible. The application of MCS pre-operatively is not a substitute for aggressive medical management, a timely palliative procedure, or an appropriate corrective intervention; rather, it should be used as an adjunct to be considered prior to dire clinical scenarios.
Post-operative
Post-operative LCOS can be secondary to the worsening of pre-surgical myocardial dysfunction or as a result of myocardial decompensation from the surgery itself. The latter can be brought on by an inflammatory response to prolonged cardiopulmonary bypass (CPB) or from the myocardial ischemia of protracted myocardial arrest or insufficient myocardial protection. Intrinsic myocardial dysfunction after extended cardioplegic arrest is usually linked to depletion in energy stores such as adenosine triphosphate, rendering medical therapy inadequate. Many conjecture that it takes approximately 72 hours for these energy stores to be replenished (3, 7) . Therefore, in the use of MCS in patients unable to be separated from CPB, the expectation is bridging to recovery. However, if a patient went to the OR with known severe dysfunction in the hope that the surgery would improve their hemodynamic profile, then MCS for inability to separate from bypass would be a bridge to transplant or destination. Both scenarios assume the intended operation was technically successful at correcting the lesion, for, uniformly, the literature decrees that MCS of a patient with an unresolved technical problem or an unintended residual defect is highly unsuccessful.
LCOS can manifest itself early as an inability to wean from bypass or late (i.e. hours or days) while recovering in the intensive care unit. The key issue in both situations is the timing of MCS implementation. In order to allow for reperfusion and restoration of myocardial energy stores, it is reasonable to "rest" the patient on bypass after an initial failed attempt at weaning from CPB. Institutional bias aside, most feel that failure to wean from bypass a second time and a need to double the expected vasopressor and inotropic support are good indications that MCS should be considered. This is endorsed by studies in adults that have shown the morbidity in these patients significantly increases if the surgical team persists in increasing medical therapy in the attempt to avoid MCS (3).
The patient who has "late" LCOS presents more of a problem in terms of MCS timing because there are two types. One set of patients is that which required extensive resuscitation in the OR to separate from bypass and thus arrive to the unit in compensated shock. The tolerance for declining hemodynamics or increasing inotropic support in this cohort should be minimal and MCS considered early. Another group of patients are those who had extensive procedures or known poor systemic function who do relatively well in the OR but start to "sag" six hours post-operatively. The tolerance for escalating medical therapy in these patients is higher but should not be excessive before considering support. Again, it should be emphasized that application of MCS in post-operative patients should not be a rescue therapy but rather a preemptive therapeutic maneuver before vital organs have been severely compromised. This decision is best made by experience, that is, the anticipation of situations that have a high probability of resulting in a poor outcome. Every institution has its own indicators of a worsening hemodynamic state. Our institution takes into account a broad spectrum of data including poor perfusion by physical exam, rising filling pressures, tachycardia, oliguria, arrythmias, and rising lactates.
Post-operative refractory pulmonary hypertension leading to cardio-respiratory collapse is also an indication of post-cardiotomy MCS. In most cases, MCS bridges the patient past the transient elevation in pulmonary vascular resistance (PVR) seen post-operatively.
Another indication to consider is profound cyanosis, after an operation such as can be seen after an early bidirectional Glenn, Fontan, or unifocalization. MCS may allow stabilization so that aggressive measures such as catheterization can be deployed to rule out technical issues or used as an intervention to complement surgical repair (i.e. closure of baffle leaks, coiling of systemic to pulmonary venous collaterals, or stenting of unifocalized aorta-pulmonary collaterals). Patients with cyanotic CHD who have exacerbation of their cyanosis secondary to a pulmonary infectious process especially respiratory syncitial virus may also benefit from MCS.
Cyanosis is unique among our MCS indications because it can usually be well supported by veno-venous ECMO. Advantages of this form of MCS are that it can be done percutaneously with one catheter, ensures complete oxygenation of coronary blood flow unlike veno-arterial ECMO, and provides a potential reduction in PVR secondary to the highly oxygenated blood in the pulmonary vascular bed. Veno-venous ECMO can also be quite advantageous when applied to patients with pulmonary dysfunction post-heart-lung or lung transplant. Arkansas has reported a 95% discharge rate among the cyanotic congenital heart patients it supported with venovenous ECMO (8) . Fortunately, early operative correction of many lesions and the myriad of pulmonary vasodilators (i.e. inhaled nitric oxide, sudenefil, prostacyclin, etc.) now available to us are limiting the need for MCS for cyanosis or acute pulmonary hypertensive crises.
Essential to the application of MCS in the postcardiotomy period is the assurance that a residual defect or a surgically created pathology (i.e. coronary insufficiency or new left-right shunt) is not present.
Surgically created pathology includes sternal compression and cardiac tamponade, which can respond dramatically to sternal re-opening and improve hemodynamics significantly. The outcome of post-cardiotomy MCS with a technically unsuccessful procedure is poor. An aggressive investigation (i.e. angiography or surgical re-exploration) is warranted before MCS is placed when there is a concern of a residual defect or coronary insufficiency. In summary, the application of MCS post-cardiotomy in patients with congenital defects needs to be anticipatory, individualized, and methodical.
Non-operative
This is the largest category of indications for MCS and includes many non-cardiac indications beyond the scope of this discussion, including parenchymal lung disease, acute respiratory disease, congenital diaphragmatic hernia, and sepsis.
Acute fulminant myocarditis in the pediatric population represents the rare opportunity for MCS to bridge the patient to full myocardial recovery. In fact, many have documented that the majority of such patients can recover with aggressive MCS (9) (10) (11) (12) (13) . The Extracorporeal Life Support Registry reports myocarditis patients as the cohort with the highest rate of weaning from ECMO, 58% (14) . Centers have been able to achieve survival rates of 80% using a combination of ECMO and VAD support, with a 78% rate of bridging to recovery (11) . In order to achieve such results, clinicians must not persist with medical therapy to the point of end-organ dysfunction or vascular collapse. The key to treating these patients is the ability to identify the early indicators of a poor clinical course and intervene early with MCS. Some theorize that even if one is able to usher patients through this neurohormonal inflammatory milieu, manifested clinically as an inflammatory myocardial infiltration, end-organ insufficiency, and hemodynamic compromise, without external support, the myocardium is damaged permanently at some level (i.e. structural or cellular). However, preliminary results suggest that early institution of MCS in patients with myocarditis allows for a significant degree of disease reversibility and myocardial recovery (11) . The unloading of the heart, which allows for normalization of ventricular geometry and the provision of stable hemodynamics, which results in a more favorable neurohormonal milieu, may avert permanent myocardial injury and thus the development of dilated cardiomyopathy.
Acute rejection of a cardiac graft is another situation wherein the pediatric patient with cardiac failure can be supported to recovery. The MCS in this situation supports the patient hemodynamically while the host of treatment strategies now available, including immunoglobulins and plasmapheresis, vigorously treats the patients' humoral or cellular rejection. Many feel these therapies are more effective in decompressed and well-perfused hearts that are not under the strain of attempting to provide adequate perfusion. Our group has treated nine patients for acute cardiac graft rejection with MCS (seven LVAD and two ECMO) with an 89% ability for successful explant from MCS. 88% of these patients were discharged home or bridged to retransplant. As our understanding of acute rejection increases and thus our ability to effectively treat it, MCS will become an important adjunct that will allow the circulation to be supported and the heart rested while aggressively treating acute myocardial rejection.
The next group of indications represents myocardial pathology that has a low potential for reversibility. Thus, MCS is used primarily as a bridge to transplant in patients with: end-stage congenital heart disease, cardiomyopathy (dilated, restrictive, or hypertrophic), and chronic cardiac graft rejection. Initially, many of these patients were supported with ECMO, with 50% survival (15) (16) (17) . The inability of ECMO to safely bridge patients to transplant for periods longer than 2 weeks accounts for the high mortality. Accordingly, there has been a shift in management of these patients from ECMO to long-term MCS when such devices are available. Use of long-term MCS in these patients has yielded favorable results with one and five-year survival rates after orthotopic heart transplant of over 75% and 70% respectively (18) (19) (20) . Hetzer's group in Berlin demonstrated that bridging these patients to transplant with MCS resulted in statistically similar survival rates at one and five years as patients treated with inotropes pre-transplant or electively awaiting transplant (21) . It should again be emphasized that these results are only possible if application of MCS is early, that is, before the patient is in extremis or end-organ dysfunction is significant.
An indication on the periphery of our specialty is the treatment of cardiopulmonary arrest with Rapid Resuscitation ECMO. We feel obliged to mention this indication since many in our field have championed its use, and it comprises nearly 25% of all indications for ECMO in children with CHD (22) . Most feel that the successful application of MCS to resuscitate these patients is directly proportional to the quickness of EMCO institution. Most centers concentrating on this effort have developed different strategies to streamline ECMO initiation including an organized team, an ECMO circuit that is portable and easily primed, and defined clinical protocols. Institutions such as the Cleveland Clinic keep a vacuum and CO 2 -primed ECMO circuit in the ICU at all times with a battery power supply to ensure mobility. The rapid resuscitation ECMO team is mobilized after 10 minutes of failed CPR. The primary goal is to establish cardiac output, which often necessitates the institution of ECMO with a crystalloid prime (23) . Others have modified the ECMO circuit by decreasing the priming volume to 250cc by using a hollow-fiber oxygenator, a centrifugal pump, and short tubing lengths (24) . Novel approaches such as these have resulted in more than 60% of cardiac arrest patients surviving to hospital discharge (23, 24) . These series have demonstrated that if institution of MCS with modified ECMO circuits is rapid and aggressive, it can be lifesaving in the majority of pediatric cardiac patients who arrest.
CONTRAINDICATIONS
Although it is important to consider each patient individually, extreme prematurity, very low birth weight (< 1.5 kg), severe neurological injury, and a constellation of congenital anomalies and/or chromosomal aberrations with poor prognosis, are widely accepted as contraindications for MCS. Other considerations are multisystem organ failure, sepsis, and severe lung disease, although, successful support has been demonstrated in all of these scenarios (25) (26) (27) (28) (29) (30) . Entertaining the use of MCS in patients with certain congenital heart diagnoses such as single ventricle physiology and pulmonary atresia, VSD, and major aorto-pulmonary collaterals should include careful consideration for whether the patients are eventual candidates for surgical correction, transplant, or are even capable of benefiting from MCS. As the field of MCS matures, the use of terminology such as absolute and relative contraindications has begun to fade as experience, data driven medical management, and the consideration of medical feasibility, resource allocation, and ethical issues have begun to guide the utilization of MCS in challenging clinical situations.
DEVICE SELECTION
The selection of a device is mainly guided by what needs to be supported (right ventricle and/or left ventricle, respiratory system), the length of support anticipated, the destination of the MCS, the size of the patient, and, accordingly, the devices available. Unlike the adult population, the device options for MCS are limited and thus dominate much of the decision making of when to institute MCS and in what capacity. Devices are usually categorized by their expected length of support: short-term denotes MCS in the ICU with no expectation of extubation; intermediate-term denotes MCS with expected extubation and physical rehabilitation in a hospital setting; and longterm denotes an intracorporeal MCS system designed for outpatient support (Tabs. II and III). Throughout this text the parameters of age younger than or equal to 18 yrs is used to define the pediatric population. The parameter of weight > 40 kg was chosen to allow readers an idea if a device was being applied in a "true" pediatric (not only in age but small size) patient or in an adult size patient who happened to be less than 18 years old. A child weighing over 40 kg is likely to have the MCS options of the adult population, whereas body size is a major limitation in device availability in the pediatric population weighing less than 40 kg. Figure  1 provides a comprehensive overview of each of the ventricular assist devices described below in table format. The information used to complete this table was collected directly from the companies involved via websites and personal communications with each company, including the number of devices implanted and is therefore regarded as highly accurate as of 2005. The table should be used as a companion to the descriptions below as it details key features of the devices including pump size and intended patient body surface area specifications.
Short-term

Intra-aortic balloon pumps
The concept of a counter-pulsation or "diastolic augmentation" device was first conceived of in the late 1950s by Harken (31, 32) . Located in the proximal descending aorta, the balloon expands during diastole, increasing pressure, and therefore blood flow, to the coronary arteries. As the balloon deflates, it generates a small vacuum that pulls blood into the aorta. This occurs immediately before systole, effectively reducing afterload and boosting cardiac output. Inflation and deflation are linked to intra-aortic pressure or electrocardiogram data.
Use of the device has been limited in the pediatric cohort, largely because the balloon's inflation cycle does not synchronize well with faster heart rates, and the pediatric aorta is more elastic than that of the adult, which renders the reduction in afterload minimal, as the aorta recoils upon deflation. Another disadvantage is the technical challenge of inserting an IABP in the pediatric aorta via the even smaller femoral artery. However, recently certain manufacturers (i.e. Datascope, Inc ® ) have created pediatric systems with balloon volumes down to 2.5 cc (6 mm diameters inflated) and catheters ranging from 4.5 to 7.0 Fr, respectively. This new technology has changed insertion techniques in children from the previously common practice of direct aortic insertion to femoral artery insertion as documented by the most ECMO ECMO has been applied over 10,000 times since the early 1970s and has become the mainstay of MCS for the pediatric population. Unlike the adult patient whose cardiac pathology centers on left ventricular failure and thus usually requires only ventricular assistance, the child with CHD often has hypoxia, pulmonary hypertension, and bi-ventricular failure to contend with, thus requiring full cardiopulmonary support such as ECMO. This type of MCS not only provides reliable bi-ventricular and complete respiratory support but also can be easily and rapidly employed through central or peripheral cannulation to a child of almost any size.
ECMO support presents many challenges however, beginning with the circuit itself. The complex integration of blood interfacing parts requires continuous monitoring, and excludes the potential for intracorporeal support. Complications include hemolysis leading to bleeding tendencies, thrombosis, a high incidence of neurological events, and continuous stimulation of the inflammatory/ immune cascades. ECMO also demands continuous, high-level monitoring in order to ensure complete heparinization and to check for thrombus formation. Furthermore, the oxygenator requires multiple changes over an extended period of support.
Even though individual institutions have reported survival rates of 60 to 70% in series of 10 to 30 patients, the Extracorporeal Life Support System with over 3,300 pediatric cardiac patients (including 1,385 neonates) reported survival rates of 40% (35, 36) . This survival rate has not changed significantly in the past decade (37-40). More troubling is the fact that on long-term follow-up, more than 60% of survivors suffer from moderate to severe neurological impairment (41) . However, in the Boston series (follow-up 4yrs), greater than 90% of children discharged post-MCS were in NYHA class I or II and 100% had normal systemic ventricular function (41) .
ECMO remains the primary form of MCS for most neonates and infants with CHD, especially in the USA. 
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However, the high rate of neurological injury and the unchanging hospital survival rate of 40% with ECMO have heightened the awareness that many congenital heart patients may be better managed by isolated ventricular or bi-ventricular support.
Centrifugal VADs
Centrifugal pumps are the most commonly used cardiac assist devices owing to their wide availability, relative simplicity of operation, accommodation of all patient sizes, and low cost. The same centrifugal pump models used in VAD support are routinely used for ECMO and cardiopulmonary bypass as well. The pumping mechanism involves channeling blood axially through a vortex created by a rotating component(s). The blood exits the pump peripherally in a non-pulsatile fashion. The mode of operation is asynchronous, that is, the pumps are programmed to pump per unit time regardless of volume or native heart contraction. However, they are sensitive to afterload, allowing a physiologic-like response to pressure changes. As such, mean arterial pressure generated on a centrifugal pump is a reflection of both intravascular volume and revolutions per minute. The centrifugal pump design reduces the risk of trauma to blood cells and generates less of an inflammatory response than conventional VADs (42, 44) . A major shortcoming is their inability to support extubated patients. Duration of support is usually less than five days with the threat of sepsis, bleeding, and device failure prohibiting support much beyond 10 to 12 days (45, 46). Golding was the first to report the use of a centrifugal pump as a VAD in 1980 (45, 47) . Since then, numerous, more sophisticated centrifugal pumps have become available, as are listed in Table IV .
BioMedicus BP-50 ®
The Medtronic ® BioMedicus Bio-Pump is the most common centrifugal pump used for VAD support in the pediatric population. It can be used for left, right, or biventricular assistance. Owing to a small-caliber pump, the BP-50, so named for the volume of blood the pump head accommodates, 50 cc, and the system's ability to accurately monitor flow down to 0.5 l/min, the Bio-Pump can provide MCS in the infant population. The BioMedicus utilizes spinning polycarbonate rotator cones to create the centrifugal force, which provides excellent retention of micro air bubbles. The outlet design is a vertical profile, which has been shown to reduce shear and hemolysis when compared with the more conventional circular profile (48) . Per Karl et al regarding their experience with 95 infants and children, the overall successful explant probability was 66% and the probability of hospital discharge was 40%. Age and weight were not associated with an increased risk of death (p > 0.05) (46). Thuys et al reported their experience with infants and children below 6 kg body weight. The successful explant rate was 63%. Of those successfully explanted, 64% were discharged from the hospital (40% of total) and 79% of these were alive one year later (31% overall) (45) .
Levitronix CentriMag ®
The Levitronix CentriMag is a centrifugal pump marketed commercially in Europe but available in the US as an investigational device only. It has been used in one pediatric patient to date (25 kg) . It can be used as a left, right, or bi-ventricular assist device. The pump employs a magnetically levitated spinning impeller to create the centrifugal force. A lack of rotating bearings reduces turbulent flow, stagnation, and potential thrombus formation as well as hemolysis (49).
Short-term pneumatic-chamber VADs
Abiomed BVS5000 ® , AB5000 ® Abiomed" has developed two VADs for use as a bridge to recovery post cardiotomy, the BVS5000 and the AB5000. The BVS5000 was the first FDA approved extracorporeal VAD. Both devices can be used for left ventricular, right ventricular or bi-ventricular assistance. The BVS5000 has more experience in the pediatric cohort than the AB5000, with 50 placements (6 patients < 40 kg) of the former compared to only four of the latter. The pumps operate via a pneumatically driven chamber. This mechanism employs pneumatic compression of a bloodfilled sac located inside the chamber; the flow generated is pulsatile. The Abiomed series features two modes of operation, asynchronous and volume-dependent. In the volume-dependent mode, the chamber ejects when it is filled with blood. This allows for some physiologic variation in pulse rate. The pumps utilize the same cannulae and console. Consequently, they can be interchanged after installation without resternotomy. This allows for a transition during recovery, if appropriate, from the less mobile BVS5000 to the AB5000, which does offer ambulation, albeit restricted (50). Ashton et al, reviewing their experience with the BVS5000 in four older children and adolescents, reported a successful explant rate of 100%, with three being bridged to transplant and one to recovery of myocardial function (27) .
Intermediate-term
Intermediate-term pneumatic-chamber VADs
The intermediate-term VADs are all paracorporeal, pneumatic-chamber pumps. They can assist left, right, or bi-ventricular function. As described in the previous section, the pneumatic-chamber VADs are composed of a flexible sac encased in a firm exterior. Blood is channeled into the sac and air is released into the chamber, compressing the sac and ejecting blood in a pulsatile fashion. An advantage of these devices is that they allow for patient extubation, ambulation (most consoles are large, but mobile), and transition out of the ICU (outpatient support is generally not available).
Thoratec VAD ®
The Thoratec VAD has been used in the MCS of over 200 patients 18 years old or younger (150 patients < 40 kg), making it the VAD with the most pediatric experience in the world. Despite our classification of it as an "intermediate-term" device, the ThoratecVAD has sustained a patient for over three years. It is FDA approved for use as a bridge to recovery or transplantation. This system features three modes of operation, asynchronous, volume-dependent, and synchronous. The synchronous mode couples pump ejection with native heart contraction. Full outpatient support is accessible if hospital discharge is indicated (51) . Regarding voluntary feedback from 184 pediatric patients placed on the VAD, Thoratec Corporation ® reports that 91 were bridged to transplant and 15 were explanted secondary to myocardial recovery for a successful explant rate of 58% (52) . Regarding six adolescent patients in fulminant heart failure placed on Thoratec VADs at the Ottawa Heart Institute, Hendry et al report each was successfully bridged to transplant; furthermore, each patient survived to discharge (53) .
Medos HIA VAD ®
The Medos HIA VAD has been utilized as MCS for 140 pediatric patients worldwide, 89 under 35 kg. FDA approval is pending. The Medos system features eight different pump sizes, ranging in volume from 9 cc to 80 cc. This flexibility makes it particularly attractive for the pediatric population, as the system can be tailored to accommodate both infants and adolescents (54) . Regarding a European multi-center experience with 56 pediatric patients supported on the Medos HIA VAD, Reinhartz et al reported 11 patients were bridged to transplant and 10 were explanted secondary to myocardial recovery for an overall successful explant rate of 36% (55) .
EXCOR VAD ®
The EXCOR VAD is another German-born, pneumaticchamber pump available for use as a bridge to recovery or transplant. It has been placed in 300 pediatric patients. The EXCOR is not currently FDA approved. The pump is produced in eight different volumes ranging from 10 cc to 80 cc, giving it a distinct advantage with respect to the pediatric population; that is, the system is an option for infants as well as adolescents. The EXCOR features two different valve systems, polyurethane velum or tilting disc. 
Long-term
The long-term devices consist of pneumaticchamber, pusher-plate pneumatic, pusher-plate electric, and axial flow VADs along with total artificial hearts. These pumps are fully implantable. The distinct advantage of these systems is that most are equipped for outpatient support. This gives patients the freedom to return to their lives and reduces the substantial financial and psychological burden associated with their in-patient management (57).
Long-term pneumatic-chamber VADs
Thoratec IVAD ® After the success of the Thoratec VAD ® , Thoratec Corporation" developed a second pneumatic-chamber device modified for optimal outpatient support, the Thoratec IVAD (implantable ventricular assist device). The pump is fully implantable (in adults and larger adolescents) but can also be placed paracorporeally. To date, it has been placed in three pediatric patients, all over 40 kg. It is the only implantable VAD capable of bi-ventricular assistance. Our classification scheme includes the designation of all intracorporeally-located pumps as "longterm"; however, the IVAD has the same FDA approved indications as the Thoratec VAD. The characteristics of the pump are very similar to the Thoratec VAD including mechanism of action, valve composition, stroke volume, range of output, and modes of operation. The IVAD is slightly smaller in gross size and weighs approximately 70 g less than the original. Furthermore, the IVAD has a smooth, titanium exterior, instead of the polysulfone exterior of its predecessor. Both pumps are compatible with a mobile console, the TLC-II Driver ® (51).
Pusher-Plate VADs
HeartMate IP ® , XVE LVAS ® The HeartMate IP was designed to support left ventricular function in adults and larger adolescents. Although no longer manufactured, it will be discussed owing to its experience in the pediatric population. Thirty devices have been placed in patients below the age of 18, none in patients less than 40 kg. The pump operates via a pneumatically driven diaphragm that displaces blood from the collecting chamber and creates pulsatile flow. The HeartMate XVE is an electrically powered, highly mobile version of the IP. It is FDA approved as destination therapy and as a bridge to transplant. To date, it has been placed in 58 pediatric patients, the youngest of which was eight years old (data on # of patients under 40 kg not available). The XVE and IP are similar in terms of gross size, stroke volume, and composition. Both contain textured internal surfaces that promote endothelialization of the blood contact surface, precluding the need for systemic anticoagulation outside of antiplatelet therapy (51). Helman et al, regarding their experience with 12 adolescent patients supported on 13 HeartMate LVADs, report an overall successful explant rate of 77% with eight patients bridged to transplant and two explanted secondary to myocardial recovery (58) .
Novacor LVAS ®
The Novacor LVAS (left ventricular assist system) is designed to support left ventricular function. The system has been placed in 42 pediatric patients worldwide, all over 40 kgs. The device is FDA approved for use as a bridge to transplant; however, the Novacor LVAS has sustained a patient for over six years. Accordingly, World Heart ® is seeking FDA approval as destination therapy. The pump operates by way of two pusher plates, located on either side of a blood-collecting sac. Powered by electromagnetic energy, the plates compress the sac during ejection (59) .
Axial flow VADs
The emergence of axial flow technology is a milestone in the evolution of pediatric VADs. This technology represents the industry's efforts to develop smaller, lighter, quieter, fully implantable VADs with complete outpatient support. Axial flow pumps were engineered to assist left ventricular function as a bridge to transplant or as destination therapy. The pump engages a magnetically levitated impeller that rotates within a cylindrical chamber, usually 7-11.5 cm (3-5 in) in length. Before exiting the chamber, blood passes through a diffuser to neutralize the rotation of the flow. Axial flow VADs are valveless and most operate in an asynchronous mode (57) .
Axial flow VADs are best classified as "continuous flow VADs" rather than "non-pulsatile devices" since it has been consistently observed that after several days of support, pulsatility often develops in the arterial tracing. This phenomenon is explained by the fact that the output of axial flow VADs is dependent on the pressure difference in the inflow and outflow cannulas during the cardiac cycle. After several days, LV recovery can begin which is demonstrated by increased contractility of the unloaded left ventricle. This allows for meaningful cardiac contraction and thus rhythmic changes in the VAD inflow pressure during the cardiac cycle. This is seen in both the outflow cannula flow meter and in the arterial waveform as pulsatility. Continuous flow from these pumps has been shown clinically to provide good end-organ perfusion as measured by the indices of renal and hepatic function and to provide equal neurological perfusion as pulsatile devices as measured by levels of S-100B protein and neuron specific enolase activity (45, (60) (61) (62) .
To date, the MicroMed DeBakey VAD ® is the only FDA approved axial flow device; however, the MicroMed DeBakey VAD Child ® is available in the US as a Humanitarian Device Exemption and the HeartMate II LVAS ® and Jarvik 2000 ® are available as investigational devices (51, 56, 63, 64) .
MicroMed DeBakey VAD ® /MicroMed DeBakey VAD Child ®
The MicroMed DeBakey VAD was developed through the joint efforts of Dr. Michael DeBakey, Dr. George Noon, and the National Aeronautics and Space Administration (NASA). Two versions of the device exist, one designed for use in patients with a body surface area (BSA) greater than 1.5 m 2 , the MicroMed DeBakey VAD, and one tailored for use in patients with a BSA 0.7-1.5 m 2 , the MicroMed DeBakey Child ( Figs. 1 A and B) . The former has been placed in nine pediatric patients, including one patient below 40 kg, while the latter has been placed in five pediatric patients, three of which were below 40 kg. The MicroMed DeBakey Child was modified to suit smaller patients (not infants or neonates) by decreasing both the angle of the inflow cannula and the size of the flow probe.
The pump itself was not modified and is identical in size and function to the adult version. Although the internal surfaces are treated with a heparin coating, systemic anticoagulation is recommended (64) . Early outcome data regarding the MicroMed DeBakey Child VAD is encouraging. Three of the five patients supported on the device have been successfully bridged to transplant (65) .
HeartMate II LVAS ®
Thoratec Corporation" fashioned its version of the axial flow VADs with the HeartMate II LVAS, currently available in the US as an investigational device only. The HeartMate II has been placed in three pediatric patients, the youngest of which was 14. The inflow and outflow cannulae feature textured internal surfaces to promote endothelialization, while the internal pump surfaces are smooth (51) .
INCOR VAD ®
The INCOR axial pump is manufactured by Berlin Heart AG ® . Although not presently available in the US, the pump is undergoing clinical trials in Europe and China. The INCOR has been placed in one pediatric patient (56) .
Jarvik 2000 ®
Aside from employing axial flow technology, the Jarvik 2000 is quite unlike the devices previously described. The pump head sits inside of the left ventricle. There is no inflow cannula and the outflow cannula attaches to the descending aorta. It is the smallest of the axial flow pumps, weighing only 85 g. The patient retains a pulse while on the Jarvik 2000, but for reasons different than those previously described for other axial flow VADs. Flow is pulsatile because the device sits inside the left ventricle and operates in synchronous mode and thus ejects in concert with native ventricular ejection, maintaining pulsatile flow (63) . The Jarvik 2000 has been placed in one pediatric patient.
Total artificial heart
CardioWest total artificial heart ® Rather than assisting the native heart, the CardioWest Total Artificial Heart (TAH) was developed to completely replace the failing organ. It is FDA approved as a bridge to transplant. This system has been placed in two pediatric patients, neither patient below 40 kg body weight. The TAH is composed of two pneumatic chambers that operate via pneumatic compression of a blood-collecting sac.
Although discussed under "long-term" options for MCS and despite its intracorporeal pump location, the TAH is not equipped for outpatient support. Patient ambulation is restricted secondary to the large console that approaches the size and weight of a household refrigerator (66). Hendry et al reports the successful bridging to transplant of one adolescent patient with fulminant heart failure placed on MCS therapy with the TAH (53).
POST-OPERATIVE MANAGEMENT
Despite the advances in pediatric critical care of the congenital heart patient, mechanically supported children represent a unique challenge to the multidisciplinary critical care team. Essential to the management of these patients is the team's complete understanding of: 1) the patient's pre-MCS physiology (i.e. septal defects, systemic to pulmonary shunts, operation performed, ensuring no post-operative residual), 2) the mechanical support (i.e. cannulation, why a particular device was chosen), 3) the interaction of the particular device and native physiology, and 4) the destination of support (i.e. recovery, transplant, assessment of viability).
One of the goals of MCS is to allow the heart to recover by allowing decreased myocardial oxygen consumption and providing adequate coronary perfusion. ECMO does not necessarily provide this, since it does not directly decompress the systemic ventricle and does allow some coronary blood flow to be provided by poorly oxygenated blood ejected from the systemic ventricle. Knowledge of the patient's pre-MCS physiology will allow one to appropriately plan to avoid this situation. Large septal defects will allow for adequate decompression of the heart, and if not present, these can be created by balloon atrial septostomy (67, 68) . Increased return to the systemic ventricle can also be secondary to aortic valve insufficiency (sometimes caused by cannula position) or systemic to pulmonary shunts (aorto-pulmonary collaterals, patent ductus arteriosus, or Blalock-Taussig Shunts). When having difficulty keeping the heart decompressed especially with systemic to pulmonary shunts present, a second cannula can be placed in the left atrium and "Y" into the ECMO circuit. These shunts can also create significant run-off to the pulmonary system making systemic perfusion difficult. Therefore, one can run support at higher flow rates but should often control the shunts either surgically or via interventional cathe-terization. In patients with surgically created systemic to pulmonary shunts, controversy exists on their management. The controversy centers around the fact that when on ECMO the heart is never completely emptied, thus the lungs are not only perfused via bronchial arteries but also by some prograde pulmonary artery flow. Thus many feel that if one completely occludes the shunt in patients with shunt dependent pulmonary flow, there will be ischemic injury to the lungs (69) . However, if one leaves the shunt open as some advocate, then there can be tremendous run-off to the pulmonary system making complete decompression of the heart as well as maintaining adequate perfusion difficult. Partial occlusion of the shunt seems to most closely approximate the usual physiology of patients on ECMO (70) . Shunt dependent pulmonary flow was thought to be a contraindication of LVAD support. Many have reported successful support of these patients with the recognition that much higher flows and the appropriate upsizing of cannulae need to be considered since the VAD is supporting the pulmonary and systemic circulations (71, 72) .
In recognition of pulmonary blood flow while on ECMO and studies demonstrating the complications of prolonged lung quiescence on CPB, ventilatory support on ECMO has become the standard of care (low ventilatory rates of 10-15, tidal volumes 10-12 ml/kg, endexpiratory pressures < 10 cm H 2 O, and inspired oxygen less than 50%). In patients with significant shunting to the pulmonary vasculature, ventilatory support should be increased proportionate to the amount of shunting. Obviously, in patients with VADs full ventilator support is required.
Most patients on MCS are fluid overloaded secondary to their pre-device heart failure and resuscitative efforts. Therefore, when hemodynamically stable, one needs to be consistent and aggressive about fluid removal. Hopefully, this can be done with establishing good renal perfusion and the use of diuretics. If renal function is impaired, a continuous veno-venous hemodialysis (CVVHD) system can be incorporated into the ECMO circuit. Even though it does not provide the controlled fluid removal of CVVHD, peritoneal dialysis can also be effective in these scenarios (73, 74) .
Measurement of filling pressures just proximal to the inflow cannula along with the arterial blood pressure is essential in MCS patients for diagnosing and treating changes in their hemodynamics. Unique in the management of LVADs, is the consideration that decreased VAD flow can be secondary to a deficiency in pre-load because of right heart failure, increased PVR, or arrhythmias. The ICU should be quite familiar with treating right heart failure and/or pulmonary vascular disease with a host of therapies including inhaled nitric oxide, milrinone, prostacyclin, and sudenifil.
The decision to wean a patient from support is quite individualized in regards to the pre-device goals, the particular device, and the patient's current status.
Remembering that it takes two to three days for myocytes to rebuild their ATP stores de novo, the signs of recovery usually begin to appear approximately 48 hours after hemodynamic stability has been established (3). Weaning is not a single attempt at a given time but rather a series of assessments over two to three days. The flow of the MCS system is slowly marched down to allow the ventricle to fill and eject. TEE, the arterial tracing, and the filling pressures should give one an idea of the heart's potential to sustain adequate perfusion. Important to remember is that in bi-ventricular support, the RVAD needs to be weaned down first and turned up after the LVAD to avoid pulmonary fluid overload. In preparation of the explant, inotropic and pulmonary support should be escalated so that adequate perfusion and ventilation is maintained throughout the process. In certain situations when the hemodynamics are questionable, certain programs will leave the cannulae in but continue to run the circuit through the arterial venous bridge for several hours until they are convinced the patient is stable. In smaller children, however, the cannulae themselves may be obstructive and may not allow the heart to function maximally.
If the MCS goal was recovery post-cardiotomy, then one must consider that the chance of recovery after 3 days and especially after one week is minimal and withdrawal of device may be warranted if the patient is not a candidate for transplant or destination VAD. Withdrawal should also be strongly considered when significant neurological complications are documented. It remains critical that both physician and family maintain realistic outcome expectations in the treatment of these critically ill patients. Honest and frequent communication between physician, patient and family is essential in this endeavor.
There are several important post-operative management issues outside the scope of this chapter: 1) vasodilatory shock requiring novel therapy like vasopressin or steroids (75); 2) systemic hypertension secondary to increased renin levels and/or the relative excessive stroke volume when adult devices are placed in children; 3) timing of anticoagulation initiation post device insertion (weighing thromboembolism vs. postoperative hemorrhage); and 4) neurological monitoring (i.e. head ultrasounds for ECMO patients, identification of seizures, use of near-infrared spectroscopy) to identify and treat the high incidence of neurological complications.
CONCLUSION
The utility of mechanical circulatory support in the form of ventricular assist devices in the management of children with heart failure has finally been recognized in the industrial, governmental (i.e. NIH), and clinical arenas. Promising outcome data, especially from European centers, further fuels the growing interest and advancing technology. The literature reported above represents the experiences of some 400 pediatric patients placed on VADs with a successful explant rate of 60%, that is, six of ten patients placed on these devices survived to myocardial recovery or transplant. The vast majority of pediatric data collected concerns patients placed on extra and paracorporeal MCS, with the Thoratec VAD providing support for a large percentage of the adolescent population, and the BioMedicus, Medos HIA VAD, and the EXCOR dominating experience in the child and infant population. The innovative axial flow VAD designs have ushered in a new era of intracorporeal MCS into the artificial organ community. MicroMed Technology Inc.'s commitment to applying this technology to the pediatric population with the MicroMed DeBakey VAD Child has the potential to redefine pediatric MCS, offering a fully implantable device capable of long-term outpatient support. The ideal endpoint is incorporating these features of the MicroMed DeBakey VAD Child into a system that accommodates all pediatric patient sizes, as was pioneered by the Berlin and EXCOR. As practitioners become more familiar with the various devices and management strategies becomes more clearly defined, we expect both the successful explant rate as well as the number of medical centers providing this form of therapy will increase significantly. Such prospects are key in addressing the management dilemma associated with the ever-growing population of pediatric patients in heart failure.
